LCM
YMAB

Landscape Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Landscape Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,690
Closed -$130K – 802
2022
Q4 		$130K Buy
+26,690
New +$194K 0.02% 666

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Landscape Capital Management's YMAB Position: Q1 2023 in Review

Landscape Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 26,690 shares — an estimated $130K sold.

Landscape Capital Management first reported a position in YMAB in Q4 2022 and held it in 1 quarter. The position peaked at $130K in Q4 2022. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

  • Landscape Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Landscape Capital Management sold 26,690 Y-mAbs Therapeutics shares in Q1 2023, an estimated $130K.
  • Landscape Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 1 quarter.
  • Landscape Capital Management's Y-mAbs Therapeutics position peaked at $130K in Q4 2022.
  • 85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Landscape Capital Management's 13F filing for Q1 2023, filed 10 May 2023.